CRPC w/ Bone Metastases - Results from #280

REVIEW UroToday

Radionuclide therapy for osseous metastases in prostate cancer - Abstract January 15, 2015

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: - Abstract January 13, 2015

Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods - Abstract December 1, 2014

A unique drug distribution process for radium Ra 223 dichloride injection and its implication for product quality, patient privacy, and delineation of professional responsibilities - Abstract November 10, 2014

Important Xofigo® (radium Ra 223 dichloride) supply update: Effective immediately U.S. Xofigo production resumes November 6, 2014

Radium-223 treatment of bone metastases from castration-resistant prostate cancer - Abstract October 27, 2014

IMPORTANT DRUG INFORMATION UPDATE: Xofigo® (radium Ra 223 dichloride) injection, for intravenous use: Delaying a dose and impact on patients October 24, 2014

Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: Exploring the implications of new data - Abstract September 30, 2014

#ASTRO2014 - Impact of prior docetaxel, extent of disease, and prior bisphosphonates on hematologic safety of radium-223 dichloride from ALSYMPCA - Poster September 16, 2014

Radium-223 dichloride for the treatment of metastatic prostate cancer - Abstract September 8, 2014

Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters - Abstract September 5, 2014

Radium 223 dichloride: A multidisciplinary approach to metastatic castration-resistant prostate cancer - Abstract August 5, 2014

Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: Samarium-153-EDTMP and radium-223 - Abstract June 25, 2014

Palliative radiotherapy for prostate cancer - Abstract June 24, 2014

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223 - Abstract June 24, 2014

Managing bone metastases and reducing skeletal related events in prostate cancer - Abstract June 23, 2014

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial - Abstract June 17, 2014

Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia - Abstract May 9, 2014

An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity - Abstract December 3, 2012

Page 15 of 15